PARIS: Europe’s main stock index closed at a record high on Friday, on track for its biggest weekly gain since late January, as risk appetite was bolstered by growing bets on interest rate cuts in the region and a strong earnings season.
The pan-European STOXX 600 ended 0.7% higher, with indexes in major economies Germany and France finishing at record highs.
European shares have resumed their record-breaking rally, with the STOXX 600 notching a 3% weekly gain, after investors took a breather in April.
The euphoria around artificial intelligence and monetary policy easing, among others, had sparked bumper gains in the region’s stocks since late 2023.
Highlighting Europe’s divergence from the US Federal Reserve and boosting equities, the Bank of England hinted at summer rate cuts and Sweden’s Riksbank delivered its first cut since 2016 earlier this week.
Minutes from the ECB’s April policy meeting showed that policymakers favoured kicking off the monetary policy easing cycle in June, while remaining confident that inflation is on track to fall back to 2% next year.
“Looking beyond June, the path for the bank is anything but clear. The risk of reflation has clearly increased,” said Carsten Brzeski, global head of macro at ING Research.
“Any signs of reflation and also stronger economic activity would limit the ECB’s room for manoeuvre.” Leading sectoral gains, utilities advanced 1.4%, with Italy’s Enel climbing 3.8% following a higher first-quarter core profit. Portugal’s largest utility firm EDP climbed 3.9% after a bigger-than-expected jump in first-quarter net profit.
Retailers added 1.5%, with Zalando rising 3.3% after Berenberg upgraded the German online retailer to “buy” from “hold”.
Among M&A developments, shares of BBVA and Sabadell were up 1.3% and 0.5%, respectively, as investors assessed the developments around the first hostile banking takeover bid in Spain since the 1980s.
Anglo American advanced 1.4% after a report said mining giant Rio Tinto had considered an offer for the British miner.
Sanofi rose 1.3% after Novavax struck a licensing deal of up to $1.2 billion with French drugmaker for its COVID-19 vaccine in exchange for a stake that valued the US biotech firm at double its current market capitalisation.
On the flip side, Getinge slumped 8.8% to the bottom of the STOXX after the US FDA issued a warning on the safety of two of the Swedish medical equipment maker’s heart devices.
Symrise shed 1.4% after Berenberg downgraded the German flavour and fragrance maker to “hold” from “buy”.
Comments
Comments are closed.